Claim Missing Document
Check
Articles

Found 5 Documents
Search
Journal : Acta Interna : The Journal of Internal Medicine

Differences in lung function in various degrees of pulmonary tuberculosis sequale Iwandheny Sepmeitutu; Sumardi Sumardi; Eko Budiono
Acta Interna The Journal of Internal Medicine Vol 4, No 2 (2014): The Journal of Internal Medicine
Publisher : Faculty of Medicine Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/acta interna.16575

Abstract

Latar belakang: Tuberkulosis masih menjadi masalah kesehatan global untuk negara berkembang khususnyadi Indonesia yang merupakan urutan kelima tertinggi di dunia. Sekuele tuberkulosis dapat terjadi padasebagaian besar pasien yang mengalami penyembuhan setelah mendapatkan pengobatan. Perubahan sekueletuberkulosis menimbulkan perubahan pada paru sehingga mengalami penurunan fungsi paru.Tujuan: Penelitian ini bertujuan mengetahui perbedaan fungsi paru forced expiratory volume in one second(FEV1) dan forced vital capacity (FVC) pada berbagai derajat sekuele tuberkulosis.Metode: Desain penelitian ini adalah potong lintang pada pasien rawat jalan poliklinik BP4 Yogyakarta dariSeptember 2013 hingga sampel terpenuhi. Perbedaan dianalisis dengan uji t dan analisis normalitas denganuji Shapiro-Wilk. Perbedaan bermakna bila p< 0.05 dengan interval kepercayaan 95%.Hasil: Hasil penelitian didapatkan subyek penelitian sebanyak 44 pasien yang terdiri dari 29 (65,9%)laki-laki dan 15(34,1%) perempuan. Subyek yang memenuhi kriteria dilakukan pemeriksaan foto thorakposteroanterior (PA). Derajat keparahan foto thorak dinilai menurut indeks Willcox. Tes spirometri dilakukanuntuk mendapatkan gambaran fungsi paru berupa FEV1 dan FVC. Karakteristik dasar subyek penelitianmenurut fungsi paru menunjukkan kelainan restriksi yang paling banyak yaitu 28 (60,9%). Perbedaan fungsiparu FEV1 bermakna pada derajat ringan dengan derajat berat (p= 0,024) dan bermakna pada fungsi paruFVC pada derajat ringan dengan derajat berat (p= 0,031).Kesimpulan: terdapat perbedaan bermakna fungsi paru FEV1 dan FVC pada derajat ringan dengan derajatberat.Kata kunci: Sekuele tuberkulosis, fungsi paru, indeks Willcox.ABSTRACTBackground: Tuberculosis remains a global health problem to developing countries, especially in Indonesiawhich is the fi fth highest in the world. Tuberculosis sequelae can occur on most patients who experiencedhealing after treatment. Tuberculosis sequelae changes cause changes in the lungs so that the decline inlung functions.Objective: This study was to determine differences in lung function, forced expiratory volume in one second(FEV1) and forced vital capacity (FVC) at various degrees of sequelae tuberculosis.Method: This is a cross-sectional study in an outpatient BP4 Yogyakarta from September 2013 until thesample met. Differences were analyzed by t-test and analysis of normality with Shapiro-Wilk test. Signifi cantdifference is when P <0.05 with 95% confi dence intervals.Result: The study subjects were 44 patients consisted of 29 (65.8%) males and 15 (34.1%) women. Subjectswho met the criteria examined thoracic images posteroanterior (PA). The degrees of severity of thoracicimages were assessed by Willcox index. Spirometry tests performed to get an overview of lung functionsuch as FEV1 and FVC. Basic characteristics of the study subjects according to pulmonary functionabnormalities restriction showed at most that 28 (63.6%). Signifi cant differences in FEV1 lung function in mild degree with severe degree (p = 0024) and FVC signifi cantly in lung function in mild degree withsevere degree (p= 0.031).Conclusion: There are signifi cant differences in lung function, FEV1 and FVC at mild degree by severedegree.Keywords: Tuberculosis sequelae, pulmonary function, index Willcox
Effects of Erdosteine Administration in Serum C-Reactive Protein Level in Stable Chronic Obstructive Pulmonary Disease Patients Eko Budiono; Neneng Ratnasari; Lina Tjandra
Acta Interna The Journal of Internal Medicine Vol 7, No 1 (2017): Acta Interna The Journal of Internal Medicine
Publisher : Faculty of Medicine Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1638.013 KB) | DOI: 10.22146/actainterna.48439

Abstract

Background.  Systemic inflammation contributes to the development of intrapulmonary and extra pulmonary disorders, and as an independent risk factor for exacerbation of chronic obstructive pulmonary disease (COPD) has proven. The use of corticosteroids as anti-inflammatory agents has limitation for their undesirable side effects and different efficacy among the patients. Erdosteine, a mucolytic agent widely used in COPD, has been proven to be able to inhibit several mediators such as reactive oxygen species (ROS) and eicosanoids, which are involved in oxidative stress and inflammation.Objective. This study aimed to discover the effects of erdosteine administration in serum C - reactive protein (CRP) level in stable COPD patients.Methods. The research was a randomized controlled trial, which compared add-on therapy used erdosteine 300 mg bid versus placebo, for 10 days, combined with COPD standard treatments. The patients was recruited at RSKP Respira Yogyakarta outpatient clinics. Diagnoses were confirmed used spirometry based on GOLD criteria. Evaluation of CRP levels was hold before treatment and on the eleventh day, used highly sensitive quantitative immunometric assay.Result. Thirty-eight legible COPD patients recruited and randomly assigned to either erdosteine group or placebo group. One patient in erdosteine group was drop out because of exacerbation and one patient from each group were lost to follow up. There are 35 subjects (97.1% men, age range 40-77 years, median FEV1 0.83 (0.50-10.08) L, hs-CRP 0.84 (0.18-18) mg/L) who completed the study, 19 subjects in erdosteine and 16 subjects in placebo group. Baseline characteristics were similar between two groups. There were no significant decreases in median hs-CRP level in erdosteine vs. placebo group at day 11 (-0.10 (-16.16-+4.31) vs. 0.005 (-11.7-+11.03) mg/L; p 0.275). In COPD GOLD 3 sub-population, hs-CRP serum level decline was greater in erdosteine group compared to placebo (-0.56 (-16.16-+0.44) vs. 0.11 (-11.7- +11.03) mg/L;  p 0.03) this might be related to greater oxidative stress in severe COPD that makes antioxidative effects of erdosteine reduce CRP more significantly in severe COPD.Conclusion. Effects of erdosteine supplements, 300 mg bid for 10 days, could decrease hs-CRP level in erdosteine insignificantly compared to placebo. Keywords: table COPD, C-reactive protein, erdosteine, FEV1, GOLD
Infl uence of Pursed-Lips Breathing to Improve Quality of Life in Chronic Obstructive Pulmonary Disease Patients Meldy Muzada Elfa; Eko Budiono; Heni Retnowulan
Acta Interna The Journal of Internal Medicine Vol 9, No 1 (2019): Acta Interna The Journal of Internal Medicine
Publisher : Faculty of Medicine Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (160.87 KB) | DOI: 10.22146/actainterna.50901

Abstract

Background. Worsening of Chronic Obstructive Pulmonary Disease (COPD) may decrease the quality of life of patients. Rehabilitation of patients with COPD may increase exercise tolerance and improve quality of life. Pursed-Lips Breathing (PLB) activates abdominal muscles during expiration for improving gas exchange and oxygen saturation in the arteries, increasing the tidal volume and reduce shortness of breath, anxiety, and tension thus improving the quality of life. St George's Respiratory Questionnaire (SGRQ) was a tool to measure the quality of life of patients with COPD, which has been validated. Patients with improved quality of life were characterized by a decrease in the SGRQ score after PLB training.Aims. Analyze the effect of improved quality of life in patients with stable COPD using PLB + standard therapy compared to standard therapy only.Methods. This research used an open-label Randomized Controlled Trial (RCT) design and conducted in patients with COPD stages 2 and 3. It was performed in Rumah Sakit Khusus Paru (RSKP) Respira Bantul, Yogyakarta. The study group was composed of 47 subjects, who continued the previous standard therapyand performed PLB 8 minutes once a day for 28 days. The placebo group (44 samples) continued the previous standard therapy alone. Measuring the quality of life using the SGRQ performed in both groupsbefore and after the experiment. Statistical analysis included independent t-test and Mann Whitney U-test.Results. Th ere were improvements in the quality of life that clinically characterized by a decrease in SGRQ total score of 12.19 points out of 100 points total in the PLB group. Th ere was a very significant difference in the decline in total SGRQ score between the study group and placebo groups (p <0.001).Conclusion. Pursed-Lips Breathing (PLB) improves the quality of life of patients with stable COPD was characterized by a decrease in SGRQ of 12.19 points out of 100 points total.Keywords.  COPD (Chronic Obstructive Pulmonary Disease),  PLB (Pursed-Lips Breathing),  SGRQ (St George’s Respiratory Questionnaire),  quality of life
Prognostic Nutritional Index (PNI) as a Prognostic Factor in Stage IV Lung Adenocarcinoma Subroto, Subroto; Budiono, Eko; Sumardi, Sumardi
Acta Interna The Journal of Internal Medicine Vol 11, No 1 (2021): Acta Interna The Journal of Internal Medicine
Publisher : Faculty of Medicine Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/actainterna.94627

Abstract

Background. Based on nutritional and immunological indicators, the Prognostic Nutritional Index (PNI) is one of the prognostic indicators besides the Platelet-to-Lymphocyte Ratio (PLR) and Glasgow Prognostic Score (GPS). PNI can serve as a biomarker to help guide clinical practice and promote clinical outcomes for lung cancer patients. PNI was superior to Neutrophil- to- Lymphocyte Ratio (NLR) in the prediction of progression-free survival (PFS) and overall survival (OS). Objectives. To analyze the association between a low PNI score (PNI <40) and increased risk of mortality among stage IV pulmonary adenocarcinoma patients.Methods. A cohort-retrospective study was performed by extracting PNI data from medical records and the mortality of patients with stage IV pulmonary adenocarcinoma. A total of 265 patients met the inclusion and exclusion criteria, based on the medical records of patients with stage IV pulmonary adenocarcinoma who were hospitalized at Dr. Sardjito hospital Yogyakarta between January 1st, 2016 and July 1st, 2019. PNI score were calculated as follows: 10 x serum albumin (g/dl) + 0.005 x lymphocyte count (per mm3). Mortality was considered six months since the diagnosis. Chi-square tests were used to analyze the proportions of mortality and confounders. Multiple logistic regression tests were used to analyze the association between PNI and mortality.Results. Subjects with PNI score <40 were at risk of mortality three times higher than subjects with PNI score ≥40 (adjustedOR 3.356, 95% CI 1.165 - 9.670, p = 0.025).Conclusion. PNI score significantly affected the mortality in patients with stage IV pulmonary adenocarcinoma.
Prolong QTc Interval in Ethionamide-Induced Hypothyroidism in the Treatment of Multidrug Resistant Tuberculosis (MDR TB) Pratiwi, Dekritiana Dian; Budiono, Eko
Acta Interna The Journal of Internal Medicine Vol 12, No 1 (2023): Acta Interna The Journal of Internal Medicine
Publisher : Faculty of Medicine Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/actainterna.98166

Abstract

Background. Ethionamide, as part of multidrug resistant tuberculosis (MDR TB) treatment, is an antibiotic classified by WHO as a second-line drug with bactericidal property. Administration of ethionamide therapy is associated with the incidence of hypothyroidism in MDR TB patients. The resulting hypothyroidism can be a factor that triggers QTc interval prolongation on electrocardiogram (ECG) during anti-tuberculosis treatmentCase Presentation. A 77-year-old man with a history of pulmonary TB treatment one year ago, returned to undergo the intensive phase of pulmonary TB treatment for two months. Sputum evaluation at the end of the phase showed positive smear results, and the patient was diagnosed with MDR TB after further examination. Before starting MDR TB treatment, an initial ECG examination (QTc interval 0.41 seconds), TSH, and FT4 level were found to be within normal limits. MDR TB regimen including ethionamide 750 mg/day was given for the treatment. In the third month of treatment, the patient was diagnosed with hypothyroidism suspected to be related to ethionamide. In the seventh month of treatment, the patient complained of sudden weakness and QTc interval prolongation in the ECG (0.48 seconds). Ethionamide was stopped and the ECG was evaluated. No QTc interval prolongation was found after stopping ethionamide.Conclusion. This case emphasizes the importance of monitoring side effects arising from anti-tuberculosis treatment, especially ethionamide. Accuracy in diagnosing and following up the side effects of ethionamide administration in MDR TB patients is necessary to prevent worse cardiac events.